120 studies found for:    vemurafenib
Show Display Options
Rank Status Study
1 Active, not recruiting BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: Vemurafenib
2 Recruiting Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
Conditions: Solid Tumors;   Hematologic Cancers;   Metastatic Cancers
Intervention: Drug: Vemurafenib
3 Recruiting The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
Condition: Melanoma
Intervention: Drug: Vemurafenib
4 Recruiting Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas
Condition: Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
Intervention: Drug: Vemurafenib
5 Active, not recruiting Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Condition: Thyroid Cancer
Interventions: Biological: KTN3379;   Drug: vemurafenib
6 Completed
Has Results
Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
Condition: Melanoma [C04.557.465.625.650.510]
Intervention: Drug: Vemurafenib
7 Recruiting Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Cobimetinib
8 Active, not recruiting
Has Results
A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
Condition: Malignant Melanoma
Intervention: Drug: Vemurafenib
9 Recruiting Bioavailability Study of Vemurafenib in Patients With BRAF^V600 Mutation-Positive Malignancies
Condition: Malignant Melanoma, Cancer
Interventions: Drug: Vemurafenib;   Drug: ^14 C-labeled vemurafenib
10 Recruiting Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis
Condition: Malignant Melanoma
Intervention: Drug: Cobimetinib + Vemurafenib combination treatment
11 Completed
Has Results
A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)
Condition: Malignant Melanoma, Neoplasms
Interventions: Drug: Rifampin;   Drug: Vemurafenib
12 Withdrawn Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
Condition: Melanoma
Interventions: Drug: Cobimetinib;   Drug: Vemurafenib
13 Recruiting ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma
Condition: Stage IIIB-C Melanoma
Intervention: Drug: Vemurafenib and Cobimetinib
14 Active, not recruiting Study of Vemurafenib, Carboplatin, and Paclitaxel
Condition: Advanced Cancers
Interventions: Drug: Vemurafenib;   Drug: Carboplatin;   Drug: Paclitaxel
15 Terminated Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Condition: Advanced BRAF-mutant Cancers
Interventions: Drug: PX-866;   Drug: vemurafenib
16 Terminated
Has Results
BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Condition: Malignant Melanoma
Intervention: Drug: vemurafenib
17 Completed Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib
Condition: Malignant Melanoma Stage IV
Intervention: Drug: Fotemustine + Vemurafenib
18 Completed
Has Results
A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
Condition: Neoplasms
Intervention: Drug: Vemurafenib
19 Terminated Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Condition: Active Melanoma Brain Metastases
Interventions: Drug: Cobimetinib;   Drug: Vemurafenib
20 Recruiting Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
Condition: Melanoma
Interventions: Drug: High-dose Interferon alfa-2b;   Drug: Vemurafenib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.